137 related articles for article (PubMed ID: 27994486)
1. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.
Gizzo S; Garcia-Velasco JA; Heiman F; Ripellino C; Bühler K
Int J Womens Health; 2016; 8():683-689. PubMed ID: 27994486
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.
Xue W; Lloyd A; Falla E; Roeder C; Papsch R; Bühler K
Int J Womens Health; 2019; 11():319-331. PubMed ID: 31191040
[No Abstract] [Full Text] [Related]
3. Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.
Lehmann M; Arbo E; Pouly JL; Barrière P; Boland LA; Bean SG; Jenkins J
Eur J Obstet Gynecol Reprod Biol X; 2024 Jun; 22():100311. PubMed ID: 38741750
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2018 Nov; 21(11):1096-1101. PubMed ID: 30113238
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.
Grynberg M; Murphy C; Doré C; Fresneau L; Paillet S; Petrica N; Frédérique M; Ravonimbola H
J Med Econ; 2018 Nov; ():1-15. PubMed ID: 30461330
[TBL] [Abstract][Full Text] [Related]
6. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.
Patel NH; Patel NH; Patel MN; Bhadarka HK; Vyas KS
J Hum Reprod Sci; 2023; 16(2):148-155. PubMed ID: 37547084
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis.
Li H; He W; Lin H; Du A; Zhang X; Yang H; Qu S
Risk Manag Healthc Policy; 2024; 17():1387-1394. PubMed ID: 38828103
[TBL] [Abstract][Full Text] [Related]
10. A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.
Barrière P; Hamamah S; Arbo E; Avril C; Salle B; Pouly JL; Jenkins J;
J Gynecol Obstet Hum Reprod; 2023 Jan; 52(1):102510. PubMed ID: 36403900
[TBL] [Abstract][Full Text] [Related]
11. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
12. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?
de Mora F; Howles CM
Drug Discov Today; 2022 Aug; 27(8):2071-2075. PubMed ID: 35490965
[TBL] [Abstract][Full Text] [Related]
13. In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f).
Mastrangeli R; Satwekar A; Cutillo F; Ciampolillo C; Palinsky W; Longobardi S
PLoS One; 2017; 12(9):e0184139. PubMed ID: 28880909
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation Pattern and
Riccetti L; Sperduti S; Lazzaretti C; Klett D; De Pascali F; Paradiso E; Limoncella S; Potì F; Tagliavini S; Trenti T; Galano E; Palmese A; Satwekar A; Daolio J; Nicoli A; Villani MT; Aguzzoli L; Reiter E; Simoni M; Casarini L
Front Endocrinol (Lausanne); 2019; 10():503. PubMed ID: 31396162
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
Šprem Goldštajn M; Dumančić S; Mikuš M
J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
[TBL] [Abstract][Full Text] [Related]
17. RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain.
Lass A; Montgomery SM
J Med Econ; 2019 Apr; 22(4):379-380. PubMed ID: 30694085
[No Abstract] [Full Text] [Related]
18. Reply: RE: a cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2019 Apr; 22(4):381-382. PubMed ID: 30691336
[No Abstract] [Full Text] [Related]
19. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha.
Barakhoeva Z; Vovk L; Fetisova Y; Marilova N; Ovchinnikova M; Tischenko M; Scherbatyuk Y; Kolotovkina A; Miskun A; Kasyanova G; Teterina T; Zorina I; Belousova N; Morozova E; Yakovenko S; Apryshko V; Sichinava L; Shalinа R; Polzikov M
Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():6-12. PubMed ID: 31400644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]